Oleanolic Acid Suppresses Aerobic Glycolysis in Cancer Cells by Switching Pyruvate Kinase Type M Isoforms

被引:49
|
作者
Liu, Jia [1 ,2 ]
Wu, Ning [1 ]
Ma, Leina [4 ]
Liu, Ming [1 ]
Liu, Ge [1 ,2 ]
Zhang, Yuyan [1 ]
Lin, Xiukun [1 ,3 ]
机构
[1] Chinese Acad Sci, Inst Oceanol, Qingdao, Peoples R China
[2] Univ Chinese Acad Sci, Grad Sch, Beijing, Peoples R China
[3] Capital Med Univ, Dept Pharmacol, Beijing, Peoples R China
[4] Ocean Univ China, Sch Med & Pharm, Dept Mol Biol, Qingdao, Peoples R China
来源
PLOS ONE | 2014年 / 9卷 / 03期
关键词
METABOLISM; EXPRESSION; MTOR; PKM2;
D O I
10.1371/journal.pone.0091606
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Warburg effect, one of the hallmarks for cancer cells, is characterized by metabolic switch from mitochondrial oxidative phosphorylation to aerobic glycolysis. In recent years, increased expression level of pyruvate kinase M2 (PKM2) has been found to be the culprit of enhanced aerobic glycolysis in cancer cells. However, there is no agent inhibiting aerobic glycolysis by targeting PKM2. In this study, we found that Oleanolic acid (OA) induced a switch from PKM2 to PKM1, and consistently, abrogated Warburg effect in cancer cells. Suppression of aerobic glycolysis by OA is mediated by PKM2/PKM1 switch. Furthermore, mTOR signaling was found to be inactivated in OA-treated cancer cells, and mTOR inhibition is required for the effect of OA on PKM2/PKM1 switch. Decreased expression of c-Myc-dependent hnRNPA1 and hnRNPA1 was responsible for OA-induced switch between PKM isoforms. Collectively, we identified that OA is an antitumor compound that suppresses aerobic glycolysis in cancer cells and there is potential that PKM2 may be developed as an important target in aerobic glycolysis pathway for developing novel anticancer agents.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis
    Hu, Mingyue
    Chen, Xiangxu
    Ma, Li
    Ma, Yu
    Li, Yuan
    Song, Huihui
    Xu, Jiajia
    Zhou, Lingna
    Li, Xiaoxue
    Jiang, Yuhui
    Kong, Bo
    Huang, Peilin
    JOURNAL OF CANCER, 2019, 10 (08): : 1870 - 1878
  • [22] Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming
    Li, Qingran
    Cao, Lijuan
    Tian, Yang
    Zhang, Pei
    Ding, Chujie
    Lu, Wenjie
    Jia, Chenxi
    Shao, Chang
    Liu, Wenyue
    Wang, Dong
    Ye, Hui
    Hao, Haiping
    MOLECULAR & CELLULAR PROTEOMICS, 2018, 17 (08) : 1531 - 1545
  • [23] CRITICAL ROLES OF PYRUVATE KINASE MUSCLE ISOZYME M2-DEPENDENT GLYCOLYSIS IN THE INTERACTIONS BETWEEN PANCREATIC STELLATE CELLS AND CANCER CELLS
    Masamune, Atsushi
    Hamada, Shin
    Yoshida, Naoki
    Shimosegawa, Tooru
    GASTROENTEROLOGY, 2017, 152 (05) : S190 - S190
  • [24] Small ubiquitin-like modifier 1 modification of pyruvate kinase M2 promotes aerobic glycolysis and cell proliferation in A549 human lung cancer cells
    An, Shuxian
    Huang, Liangqin
    Miao, Ping
    Shi, Liang
    Shen, Mengqin
    Zhao, Xiaoping
    Liu, Jianjun
    Huang, Gang
    ONCOTARGETS AND THERAPY, 2018, 11 : 2097 - 2109
  • [25] THE EFFECT OF L-CYSTEINE AND ITS DERIVATIVES ON AEROBIC GLYCOLYSIS AND PYRUVATE-KINASE ACTIVITY IN TUMOR-CELLS
    GUMINSKA, M
    KEDRYNA, T
    MARCHUT, E
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (09): : 1286 - 1286
  • [26] Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2
    Li, Shumin
    Huang, Peng
    Gan, Junqing
    Ling, Xiaodong
    Du, Xiaoxue
    Liao, Yuanyu
    Li, Lisha
    Meng, Yu
    Li, Yanjing
    Bai, Yuxian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 854 : 232 - 239
  • [27] Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo
    Yuan, Quan
    Yu, Honghao
    Chen, Jianhua
    Song, Xiaoyu
    Sun, Li
    EXPERIMENTAL CELL RESEARCH, 2018, 362 (01) : 209 - 216
  • [28] Fructose-1,6-bisphosphatase 2 represses cervical cancer progression via inhibiting aerobic glycolysis through promoting pyruvate kinase isozyme type M2 ubiquitination
    Wang, Bi
    Yuan, Yingnan
    Zou, Yin
    Qi, Zhengjun
    Huang, Guijia
    Liu, Yi
    Xia, Shan
    Huang, Yu
    Huang, Zhi
    ANTI-CANCER DRUGS, 2022, 33 (01) : E198 - E206
  • [29] Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells
    Fadi Almouhanna
    Biljana Blagojevic
    Suzan Can
    Ali Ghanem
    Stefan Wölfl
    Cancer & Metabolism, 9
  • [30] Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells
    Almouhanna, Fadi
    Blagojevic, Biljana
    Can, Suzan
    Ghanem, Ali
    Woelfl, Stefan
    CANCER & METABOLISM, 2021, 9 (01)